Background—Treatments that reduce mortality and morbidity in patients with heart failure
with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI) …

Context Theory and simulation suggest that randomized controlled trials (RCTs) stopped
early for benefit (truncated RCTs) systematically overestimate treatment effects for the …

Background Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients
with chronic heart failure (CHF). A substantial proportion of patients, however, experience no …

Activation of the renin–angiotensin–aldosterone system (RAAS) results in vasoconstriction,
muscular (vascular and cardiac) hypertrophy and fibrosis. Established arterial stiffness and …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Background: Limited comparative studies assessing the health‐related quality of life (HRQL)
in heart failure (HF) patients with preserved vs. low ejection fraction (LVEF) have been …

Aims The 6 min walk test (6MWT) is commonly used in clinical trials to assess treatments for
heart failure, but its ability to distinguish between effective and ineffective treatments is …

Iron deficiency is present in approximately 50% of patients with symptomatic heart failure
and is independently associated with worse functional capacity, lower quality of, life and …

Background: The role of angiotensin-receptor blockers (ARBs) in treating patients with
chronic heart failure and high-risk acute myocardial infarction (MI) has been controversial …

Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly
improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF) …